Investigating metastasis in colon cancer patients undergoing surgery
Official title: Right Gastroepiploic Mesentery Metastasis in Advanced Colon Cancer Locating at or Close to the Hepatic Flexure
Run by Tongji Hospital · NCT04980287 · Data updated 2026-11-12
This study is testing how removing certain parts of the mesentery during colon cancer surgery affects the safety and outcomes for patients with tumors near the liver.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | January 12, 2021 |
| Main results expected | July 19, 2025 |
| Study ends | July 19, 2028 |
| Registry record updated | October 15, 2026 |
| Trial ID | NCT04980287 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 with biopsy-proven colorectal carcinoma located at the hepatic flexure or transverse colon, who are undergoing complete mesocolic excision.
✕Probably not a fit
Patients with synchronous colorectal carcinoma, evidence of metastasis, or a history of colorectal cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to define the incidence of mesogastrium metastasis in patients with colon cancer located at or near the hepatic flexure. It will analyze the safety and surgical outcomes of patients undergoing complete mesocolic excision with right gastroepiploic mesentery resection. Utilizing high-definition laparoscopy, the study seeks to improve understanding of the mesentery's role in colon cancer surgery and its impact on patient outcomes. The study builds on previous findings that suggest complete mesocolic excision can reduce recurrence rates and improve survival.
Why it matters
Potential benefit: If successful, this study could enhance surgical techniques and outcomes for colon cancer patients, potentially leading to better survival rates.
How similar studies have gone: Previous studies on complete mesocolic excision have shown promising results in reducing recurrence rates and improving survival, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 75 years * American Society of Anesthesiologists (ASA) score I to III * A biopsy proven histological diagnosis of colorectal carcinoma * Preoperative staging cT2-4aN0M0 or cTanyN+M0 * tumor located at hepatic flexure or transverse colon close to flexures * Undergoing complete mesocolic excision with right gastric mesentery resection * Patients have to be aware of the aim of the trial, and have signed the informed consent. Exclusion Criteria: * Synchronous colorectal carcinoma * Clinical evidence of metastasis * History of colorectal cancer or other malignant tumors * Preoperative staging cT1N0 or cT4bNany * Emergency procedure
Where it's running
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Jichao Qin, M.D./Ph.D
- Email: jcqin@tjh.thmu.edu.cn
- Phone: 008613628683363
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
-
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.
-
Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer
This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.
-
Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer
This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors
This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.